/
Oncology
Metastatic Colorectal Cancer
155
Pipeline Programs↗
205
Active Trials↗
118
Companies Involved↗
Metastatic Colorectal Cancer is a highly competitive landscape with 155 programs across 118 companies. The most active players are Shanghai Henlius Biotech, Roche, BioNTech. 42 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical29
Phase 114
Phase 270
Phase 342
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
112 of 147 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 147 classified programs, each share of the total. Modality classified for 97% of 155 pipeline programs.
Analysis
Trial Status
951
clinical trials
Completed449 · 47%
Unknown status137 · 14%
Recruiting119 · 13%
Terminated117 · 12%
Not yet recruiting46 · 5%
Active, not recruiting39 · 4%
Other44 · 5%
Clinical Trials
Trial Activity
951 trials
Page 1 of 64
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)